129 related articles for article (PubMed ID: 3484324)
1. In vivo activity of piritrexim [corrected] against Toxoplasma gondii.
Araujo FG; Guptill DR; Remington JS
J Infect Dis; 1987 Nov; 156(5):828-30. PubMed ID: 3484324
[No Abstract] [Full Text] [Related]
2. In-vitro and in-vivo activities of roxithromycin in combination with pyrimethamine or sulphadiazine against Toxoplasma gondii.
Romand S; Bryskier A; Moutot M; Derouin F
J Antimicrob Chemother; 1995 Jun; 35(6):821-32. PubMed ID: 7559193
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
4. A clinical-parasitological monotherapy cure in the treatment of experimental infection by a highly virulent strain of Toxoplasma gondii.
de Diego JA; Penin P; Arribas JR; Vázquez E; Vázquez JJ
Folia Microbiol (Praha); 1996; 41(6):513-6. PubMed ID: 9131805
[TBL] [Abstract][Full Text] [Related]
5. Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii.
Gross U; Pohl F
Curr Top Microbiol Immunol; 1996; 219():235-45. PubMed ID: 8791704
[No Abstract] [Full Text] [Related]
6. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
Martins-Duarte ÉS; de Souza W; Vommaro RC
Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
[TBL] [Abstract][Full Text] [Related]
7. Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii.
Kovacs JA; Allegra CJ; Chabner BA; Swan JC; Drake J; Lunde M; Parrillo JE; Masur H
J Infect Dis; 1987 May; 155(5):1027-32. PubMed ID: 2951446
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
9. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680
[TBL] [Abstract][Full Text] [Related]
10. Nonionic block copolymers potentiate activities of drugs for treatment of infections with Toxoplasma gondii.
Araujo FG; Slifer T
Antimicrob Agents Chemother; 1995 Dec; 39(12):2696-701. PubMed ID: 8593005
[TBL] [Abstract][Full Text] [Related]
11. In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.
Piketty C; Derouin F; Rouveix B; Pocidalo JJ
Antimicrob Agents Chemother; 1990 Aug; 34(8):1467-72. PubMed ID: 2221854
[TBL] [Abstract][Full Text] [Related]
12. Trovafloxacin is active against Toxoplasma gondii.
Khan AA; Slifer T; Araujo FG; Remington JS
Antimicrob Agents Chemother; 1996 Aug; 40(8):1855-9. PubMed ID: 8843293
[TBL] [Abstract][Full Text] [Related]
13. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models.
Barbosa BF; Gomes AO; Ferro EA; Napolitano DR; Mineo JR; Silva NM
Vet Parasitol; 2012 Jun; 187(1-2):44-52. PubMed ID: 22281151
[TBL] [Abstract][Full Text] [Related]
14. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
Mehlhorn H; Dankert W; Hartman PG; Then RL
Parasitol Res; 1995; 81(4):296-301. PubMed ID: 7624286
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice.
Martinez A; Allegra CJ; Kovacs JA
Am J Trop Med Hyg; 1996 Mar; 54(3):249-52. PubMed ID: 8600759
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in experimental toxoplasmosis: comparison of the efficacy of trimethoprim-sulfur and pyrimethamine-sulfur combinations.
Seah SK
J Trop Med Hyg; 1975 Jul; 78(7):150-3. PubMed ID: 1177347
[TBL] [Abstract][Full Text] [Related]
17. Prenatal diagnosis and treatment of congenital Toxoplasma gondii infections: an experimental study in rhesus monkeys.
Schoondermark-van de Ven EM; Melchers WJ; Galama JM; Meuwissen JH; Eskes TK
Eur J Obstet Gynecol Reprod Biol; 1997 Aug; 74(2):183-8. PubMed ID: 9306115
[TBL] [Abstract][Full Text] [Related]
18. Effect of deferoxamine alone and combined with pyrimethamine on acute toxoplasmosis in mice.
Mahmoud MS
J Egypt Soc Parasitol; 1999; 29(3):791-803. PubMed ID: 12561919
[TBL] [Abstract][Full Text] [Related]
19. Effects of pyrimethamine and sulfadiazine on the intestinal development of Toxoplasma gondii in cats.
Sheffield HG; Melton ML
Am J Trop Med Hyg; 1976 May; 25(3):379-83. PubMed ID: 937628
[TBL] [Abstract][Full Text] [Related]
20. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Jost C; Reiter-Owona I; Liesenfeld O
Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
